Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Matthew J. Sale(Babraham Institute), Simon J. Cook(Babraham Institute)
Nature Communications
November 14, 2019
Cited by 73


Related Papers